An Open-label, Prospective, Single Centre Study of the Effects of Riociguat on RIght VEntricular Size and Function in Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension
Latest Information Update: 16 Aug 2024
Price :
$35 *
At a glance
- Drugs Riociguat (Primary)
- Indications Pulmonary arterial hypertension
- Focus Therapeutic Use
- Acronyms RIVER II
- 14 Apr 2022 Status changed from not yet recruiting to recruiting.
- 07 Jul 2021 New trial record
- 29 Jun 2021 Status changed from recruiting to not yet recruiting.